Ani Pharmaceuticals Inc. (BSFA)
XDUS 
Summary
BSFA Chart
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly 60% of 2026 revenue. Cortrophin guidance was lowered by ~$30M, but H2 expectations remain intact, with Q4 growth hinging on gout salesforce productivity.
Ani Pharmaceuticals Inc. (BSFA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ani Pharmaceuticals Inc. ever had a stock split?
Ani Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Nikhil Lalwani CEO | XDUS Exchange | US00182C1036 ISIN |
| US Country | 970 Employees | - Last Dividend | 4 Jun 2012 Last Split | 5 May 2000 IPO Date |
Overview
ANI Pharmaceuticals, Inc. is a leading biopharmaceutical company that specializes in the development, manufacturing, and marketing of both branded and generic prescription pharmaceuticals, primarily in the United States and Canada. With its incorporation in 2001, the company has established a significant presence in the pharmaceutical industry, headquartered in Baudette, Minnesota. It serves a wide range of customers including retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals, underpinning its comprehensive approach to healthcare solutions.
Products and Services
- Oral solid dose productsANI Pharmaceuticals excels in manufacturing a variety of oral solid dose products, such as tablets and capsules. These are designed for ease of use and effectiveness in treatment, catering to a wide range of therapeutic areas.
- Semi-solids, liquids, and topicalsThe company also produces semi-solid formulations, liquid medicines, and topical treatments. These products offer alternatives for patients requiring different delivery methods for their medications beyond traditional oral forms.
- Controlled substancesSpecializing in the highly regulated sector of controlled substances, ANI Pharmaceuticals demonstrates its commitment to maintaining stringent quality control and regulatory compliance, ensuring safe and reliable medications for conditions that require tightly controlled ingredients.
- Potent productsANI Pharmaceuticals has the capability to manufacture potent products that require special handling and manufacturing processes due to their high potency. These products are critical for treating more severe conditions, necessitating a higher level of expertise in their production.
- Contract development and manufacturing of pharmaceutical productsAside from its own product offerings, ANI Pharmaceuticals provides contract development and manufacturing services. This allows other companies to leverage ANI's expertise and facilities for the development and manufacturing of their pharmaceutical products, highlighting ANI's flexibility and capability in supporting the broader pharmaceutical industry.
Contact Information
